drugset
drugset / Trial / NCT06420297

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06420297 ↗

Phase 3 Enrolling by invitation 160 enrolled ACADIA Pharmaceuticals Inc.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS

Timeline

Start
2024-03-11
Primary completion
2029-05
Completion
2029-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbetocin Peptide 3.2 mg Intranasal

Indications

Prader-Willi syndrome